Synosia Therapeutics develops and intends to commercialise innovative products for unmet medical needs in psychiatry and neurology. We are developing seven clinical-stage compounds acquired through strategic partnerships with Roche, Novartis and Syngenta. Our pipeline includes two marketed drugs that will be tested in new indications, extending their reach into new neurological and psychiatric diseases with high unmet medical need, including anxiety and Parkinson's disease.